Batten disease treatment market: Batten disease is most common group of disorders called Neuronal Ceroid Lipofuscinoses (NCLs). Batten disease is a rare, fatal and inherited nervous system disorder that generally begins in childhood. It is also caused by lysosome shortage. The symptoms in initial stages will be vision loss in previously healthy children followed by slow learning, personality and behavioural changes. Commonly within 2-4 years of vision loss seizures may appear. Generally, neuronal ceroid lipofuscinoses are classified into infantile NCL (INCL), late infant NCL (LINCL), juvenile NCL (JNCL) and adult NCL.Market Outline: Global Batten disease Treatment
Batten disease treatment market is driven by an increase in R&D activities for development of new treatments for batten disease. In addition, lack of effective treatment options and increase in prevalence rates of batten disease treatment market are expected to boost the market growth over the forecast period.
A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Global Batten disease Treatment market is segmented based on type of disease, treatment and distribution channel
Based on type of disease, batten disease treatment is segmented into
• Juvenile NCL (JNCL)
• Infantile NCL (INCL)
• Late infant NCL (LINCL)
• Adult NCL
• Others
Based on treatment, batten disease treatment market is segmented into
• Gene Therapy
• Drug Therapy
• Enzyme Therapy
• Others
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-c654SbFYO64MsOhu[/URL]
According to National Institute of Neurological Disorders and Stroke, Batten disease occurs in an estimated 2 to 4 of every 100,000 live birth in U.S., and it is more common in Sweden, Finland, other parts of Northern Europe, and Newfoundland, Canada. Batten disease treatment market is still in development stage.
Geographically, batten disease treatment market has been segmented into Latin America, Europe, Asia-Pacific, North America, and the Middle East & Africa. North America and Europe batten disease treatment market growth is attributed to increasing in R&D expenditure, growing awareness related to the batten disease due to various awareness programs being taken by the non-government and government organizations in the region.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in batten disease treatment market are Abeona Therapeutics Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), CereSpir Inc. (U.S.), Evotec AG (Germany), Ionis Pharmaceuticals Inc. (U.S.), Mitochon Pharmaceuticals Inc. (U.S.), and Spark Therapeutics Inc. (U.S.) to name a few.
• In April 2017, U.S. FDA has approved BioMarin Pharmaceutical Inc.’s Brineura, the first FDA approved treatment for a form of batten disease.
Get access to full summary @
[URL]https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/[/URL]
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553